Innovative Dealmaking

06:30 - 07:45 Sunrise Jog

07:45 - 08:45 Registration And Networking Breakfast

08:45 - 08:50 Welcoming Remarks

img

Andrew Mitchell

Director, Product Strategy and Marketing, Life Sciences
Intralinks

img

Kenneth Lebioda

Senior Vice President, Business and Corporate Development
Resverlogix Corp.

img

Adi Frish

Senior Vice President, Business Development and Licensing
Redhill Biopharm LTD

• Overview of the latest variations on risk sharing
• How are up front payments being minimized?
• What are the different investment vehicles being used?

img

Scott E. Goedeke

President
Viscadia

img

Stuart Mackey

Global Head of Business Development
Daiichi Sankyo

img

Christoph Pittius

Vice President, Head of Transactions
AstraZeneca

img

Peter Ginsberg

AVP, Business Development
United Therapeutics Corporation

img

Patrick Johnson

Vice President of Business Development
Allergan, Inc.

img

Rachna Khosla

Executive Director, Business Development
Amgen

1:1 Partnering Meetings

09:30 - 10:10 Opening Of 1:1 Partnering Meetings

General Session

10:10 - 10:50 Networking And Refreshment Break

1:1 Partnering Meetings

10:10 - 10:50 Opening Of 1:1 Partnering Meetings

General Session

10:50 - 11:30 Panel Discussion | From Sourcing to Alliance Management, The Ins and Outs of Hybrid Deals Stephen Thau, Partner,Morrison & Foerster Eric Risser, Senior Vice President, Business Development,MacroGenics, Inc. Nassim Usman, Chief Executive Officer,Catalyst Biosciences
The industry continues to evolve toward evermore complex transactions for the development and commercialization of products. With the increasing complexity of deal structure and collaboration objectives, effective alliance management requires new tools and approaches.
• Overview of emerging practices for deals that rely heavily on partnerships
• Establishing governance and strategies to optimize the prospects for success
• Working toward alignment internally and externally on global deals

img

Eric Risser

Senior Vice President, Business Development
MacroGenics, Inc.

img

Stephen Thau

Partner
Morrison & Foerster

img

Nassim Usman

Chief Executive Officer
Catalyst Biosciences

1:1 Partnering Meetings

10:50 - 11:30 Opening Of 1:1 Partnering Meetings

General Session

11:30 - 11:45 Biotech Spotlight | NeOnc Technologies Thomas Chen, Chief Executive Officer,NeOnc Technologies

Thomas Chen

Chief Executive Officer
NeOnc Technologies

1:1 Partnering Meetings

11:30 - 11:45 Opening Of 1:1 Partnering Meetings

General Session

11:45 - 12:00 Biotech Spotlight | Amunix Volker Schellenberger, President & CEO,Amunix

img

Volker Schellenberger

President & CEO
Amunix

1:1 Partnering Meetings

11:45 - 12:00 Opening Of 1:1 Partnering Meetings

General Session

12:00 - 12:15 Biotech Spotlight | Oncoceutics Lee Schalop, Chief Business Officer,Oncoceutics, Inc.

img

Lee Schalop

Chief Business Officer
Oncoceutics, Inc.

1:1 Partnering Meetings

12:00 - 12:15 Opening Of 1:1 Partnering Meetings

General Session

12:15 - 12:30 Biotech Spotlight | Immunomic Therapeutics, Inc. Sia Anagnostou, Senior Director, Corporate Development,Immunomic Therapeutics, Inc.

img

Sia Anagnostou

Senior Director, Corporate Development
Immunomic Therapeutics, Inc.

1:1 Partnering Meetings

12:15 - 12:30 Opening Of 1:1 Partnering Meetings

General Session

12:30 - 13:40 Networking Luncheon

1:1 Partnering Meetings

12:30 - 13:40 Opening Of 1:1 Partnering Meetings
• What are the key challenges in conducting diligence?
• What do you perceive to be the key challenges?
• What approaches are most effective in getting validated insights faster?

img

Robert Bagdorf

Vice President of Worldwide Business Development
Pfizer Inc.

img

Patrick Gallagher

Vice President of Business Development
Noven Pharmaceuticals, Inc.

img

Kathryn Gregory

Executive Director, Business Development
Purdue Pharma

img

Ashlee Dunston

Director of Healthcare Research
Guidepoint

img

Adam Marcus

Principal
DRI Capital

img

Younes Bekkali

Director, BD&L, Strategic Transactions
Boehringer Ingelheim Pharmaceuticals, Inc.

• What are the latest developments in the emerging model of companies started by VCs?
• What is the current appetite for risk across the biopharma venture community?
• How do strategies differ from large VC to new venture funds?

img

Asish Xavier

Vice President, Venture Investments
Johnson & Johnson

img

Elaine Jones

Executive Director, Venture Capital
Pfizer Inc.

img

Leon Chen

Venture Partner
OrbiMed Advisors

img

Anshul Thakral

Senior Vice President
PPD Biotech

img

Jeremy Bender

Chief Operating Officer
Tizona

img

Rajeev Dadoo

Partner
SR One

1:1 Partnering Meetings

14:20 - 15:00 1:1 Partnering Meetings

General Session

15:00 - 15:40 Networking And Refreshment Break

1:1 Partnering Meetings

15:00 - 15:40 1:1 Partnering Meetings

General Session

15:40 - 15:55 Biotech Spotlight | KLOX Technologies Alex Chang, Head, Business Development and Alliance Management,KLOX Technologies

img

Alex Chang

Head, Business Development and Alliance Management
KLOX Technologies

1:1 Partnering Meetings

15:40 - 15:55 1:1 Partnering Meetings

General Session

15:55 - 16:10 Biotech Spotlight | Sequence Bio Tyler Wish, Chief Executive Officer,Sequence Bio
img

Tyler Wish

Chief Executive Officer
Sequence Bio

1:1 Partnering Meetings

15:55 - 16:10 1:1 Partnering Meetings

General Session

16:10 - 16:25 Biotech Spotlight | Enable Injections Jeannie Joughin, Vice President, Corporate Development,Enable Injections
img

Jeannie Joughin

Vice President, Corporate Development
Enable Injections

1:1 Partnering Meetings

16:10 - 16:25 1:1 Partnering Meetings
• What data are buyers looking for?
• How can you best differentiate your product in a crowded space?
• With pharma and VCs taking a greater interest in early stage opportunities, what can biotech and academic institutions do to be most competitive?

img

Scott Shaunessy

CEO
ideaPoint

img

Steven Bartz

Director, Worldwide Licensing
Merck

img

Michael Bayewitch

Director, S&E, Biologics
Teva Pharmaceuticals USA

img

Lisa Beck

Head of Transactions, Global Business Development
Alexion Pharmaceuticals, Inc

img

Dr. Gary VanSavage

Senior Director, Transactions, Janssen Business Development
Johnson & Johnson

img

Sylvaine Cases

Senior Director, External Innovation
Sanofi

1:1 Partnering Meetings

16:25 - 17:05 1:1 Partnering Meetings

General Session

17:05 - 23:59 Monte Carlo Casino Night

1:1 Partnering Meetings

17:05 - 23:59 1:1 Partnering Meetings